Zhongze Therapeutics Announces Successful Completion Of The First-In-Human Dose Escalation Study of ZZ6398 in Healthy Volunteers

SHANGHAI, CHINA, April. 1, 2022– Zhongze Therapeutics, a clinical stage biotech company focused on the discovery, develo...

Author：Zhongze Therapeutics         Views：3359

2022

04-06

Congratulations to Our Partner Digestome Therapeutics for completing the enrollment of the first patient in Phase 1 Clinical Trial of DGX-001 (ZZ2103)

SAN FRANCISCO, March 8, 2022 – Digestome Therapeutics, a biotech company developing first-in-class therapeutics that sti...

Author：Zhongze Therapeutics         Views：2687

2022

03-14

ZHONGZE Completed Series Pre-A Round Financing of 10 million US dollars

Recently, ZHONGZE Therapeutics has completed Series Pre-A round financing of 10 million dollars. The fund will be used f...

Author：Zhongze Therapeutics         Views：2801

2021

09-30

The First-in-Man Dose of ZZ6398 Was Successfully Administered in Beijing Anding Hospital

At 8:00 on September 12, 2021 at Beijing Anding Hospital, the investigators successfully completed the first dose group ...

Author：Zhongze Therapeutics         Views：2732

2021

09-12

ZHONGZE Enters into Sublicense Agreement with GBC for Anti-Addiction Program

On September 4, 2021, ZHONGZE signed an agreement with GBC of the United States to license in a clinical Phase II anti-a...

Author：Zhongze Therapeutics         Views：3187

2021

09-04